Navigation Links
Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
Date:6/23/2008

BALTIMORE, June 23 /PRNewswire/ -- Lupin Pharmaceuticals, a subsidiary of Lupin Ltd., announced today that the Company has entered into a promotion agreement for Suprax(R) 400 mg Tablets with ASCEND Therapeutics, Inc.

Under the terms of the alliance, ASCEND Therapeutics will initiate promotion of the product in the U.S. in the month of June 2008. ASCEND has a 50-person Women's Health sales force which will detail the product primarily to Obstetricians and Gynecologists (OB/GYNs). Lupin will continue to promote the product to Pediatricians and Family Practitioners.

The antibiotic market for treatment of Urinary Tract Infections (UTIs) is USD 450 million, and the OB/GYN area is among the top three physician specialties prescribing antibiotics for treatment of UTIs.

"We are pleased to enter into this strategic alliance with ASCEND. We believe ASCEND's existing equity with the OB/GYN specialty will help Lupin to fully explore and leverage an additional opportunity for promoting Suprax(R) 400 mg Tablets. This alliance reflects Lupin's commitment to building the Suprax(R) franchise and enhancing the value of brand business in the U.S.," said Vinita Gupta, President, Lupin Pharmaceuticals, Inc.

"We are very excited about adding Suprax(R) 400 mg Tablets to our portfolio of products which we market to Women's Health professionals," said Jay Bua, President, ASCEND Therapeutics. "There are over 8 million patient visits for UTIs each year, with the vast majority of these experienced by women. Suprax(R) 400 mg Tablets is an established antibiotic with a favorable safety profile and proven track record in effectively treating UTIs and other bacterial infections. We very much look forward to a long and productive collaboration with Lupin."

About Lupin

Lupin Pharmaceuticals, Inc., headquartered in Baltimore, Maryland, is the wholly owned U.S. subsidiary of Mumbai-based Lupin Limited, a leading Indian pharmaceutical company. Lupin Limited develops, manufactures and markets a wide range of quality, affordable generic and branded generic formulations and APIs for both the developed and the developing markets of the world. Twelve of Lupin's facilities have been inspected and approved by the U.S. Food & Drug Administration.

For the year ended March 2008, Lupin's consolidated revenues and profit after tax were USD 660.23 million and USD 97.21 million, respectively.

The Company has secured a global leadership position in anti-TB products and cephalosporins and has a significant presence in the areas of cardiovasculars (prils and statins), diabetology, asthma and NSAIDs. Currently positioned among the top five pharmaceutical companies in India, the Company is committed to achieving sustainable earnings and growth for all its stakeholders. For more information, visit http://www.lupinpharmaceuticals.com.

About ASCEND Therapeutics

ASCEND Therapeutics is a biopharmaceutical company focused on the use of transdermal drug delivery technology to overcome therapeutic barriers and raise the standard of care for certain chronic conditions. For more information about ASCEND, you may visit the company's web site at http://www.ascendtherapeutics.com.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.

Suprax(R) is a registered trademark of Lupin Pharmaceuticals, Inc.

For More Information:

Contact: Atul Gokhale

General Manager -- Marketing

1-410-576-2000


'/>"/>
SOURCE Lupin Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lupin Receives USFDA Approval for Topiramate Tablets
2. Lupin Launches Ramipril Capsules
3. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
4. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
5. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
6. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
7. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
8. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
9. Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
Breaking Medicine Technology: